DBDren BioUndisclosed · San Carlos, USA · Biotech & Pharma
What changedRaised $350M, led by Juvia Group and Lightspeed Venture Partners.
The company said the funding supports support its clinical development, regulatory submission, and planned commercial launch of its lead investigational therapy, dibotatug (DR-01), expand it into additional indications, and accelerate the development of its broader pipeline across oncology, immunology, and neurology.
What nextsupport its clinical development, regulatory submission, and planned commercial launch of its lead investigational therapy, dibotatug (DR-01), expand it into additional indications, and accelerate the development of its broader pipeline across oncology, immunology, and neurology.
Where help may be relevant AfterRaise intelligenceLocal market experienceEmployment infrastructureLegal and tax setupProduct leadership
Approach preferences not yet specified